BaseSpace
Correlation
Engine-Public
Sign In
Register
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Cisplatin
,
rs2476601
,
MYC
,
T cell receptor signaling pathway
,
Ischemia
,
Heart
,
Nosology
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
antithyroid drugs
Summary
General Info
Curated Studies
Most Correlated Studies
Drug target sets for approved compounds
Broad Connectivity Map (CMAP 2.0) compound database
Neural 3D tissue constructs from H1 ESC-derived precursor cells treated with neurotoxic chemicals
Liver Pharmacology and Xenobiotic Response Repertoire
Livers of rat exposed to variety of hepatotoxic compounds
Explore Curated Studies Results
Literature
Most Relevant Literature
Approach to the Patient Considering Long-term Antithyroid Drug Therapy for Graves' Disease.
The Origin of Antithyroid Drugs.
Effect of Antithyroid Drugs Treatment Duration on The Remission Rates of Graves' Disease in Children…
Prediction for recurrence following antithyroid drug therapy for Graves' hyperthyroidism.
Predictive effect of antithyroid antibody for relapse of Graves' disease.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Antithyroid Drugs During Radioiodine Therapy
Genetic Study of Antithyroid Drugs Associated Agranulocytosis
Antithyroid Drug Treatment of Thyrotoxicosis in Young People
Change of Gut Microbiome in the Treatment of Graves' Disease
Drug Etiology of Aplastic Anemia and Related Dyscrasias
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ